The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin

The patient was a 67-year-old woman with type 2 diabetes and non-alcoholic steatohepatitis (NASH). The administration of the sodium-glucose cotransporter 2 (SGLT2) inhibitor, ipragliflozin improved her liver dysfunction clinically and histologically. The serum alanine aminotransferase (ALT) and ferr...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Akihiko, Irahara, Aya, Nakano, Atsuko, Takata, Emi, Koketsu, Yuko, Kimata, Kunie, Senda, Eri, Yamada, Hajime, Ichikawa, Kazuhito, Fujimori, Takahiro, Sumida, Yoshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675935/
https://www.ncbi.nlm.nih.gov/pubmed/28924123
http://dx.doi.org/10.2169/internalmedicine.8754-16
_version_ 1783276988326215680
author Takeda, Akihiko
Irahara, Aya
Nakano, Atsuko
Takata, Emi
Koketsu, Yuko
Kimata, Kunie
Senda, Eri
Yamada, Hajime
Ichikawa, Kazuhito
Fujimori, Takahiro
Sumida, Yoshio
author_facet Takeda, Akihiko
Irahara, Aya
Nakano, Atsuko
Takata, Emi
Koketsu, Yuko
Kimata, Kunie
Senda, Eri
Yamada, Hajime
Ichikawa, Kazuhito
Fujimori, Takahiro
Sumida, Yoshio
author_sort Takeda, Akihiko
collection PubMed
description The patient was a 67-year-old woman with type 2 diabetes and non-alcoholic steatohepatitis (NASH). The administration of the sodium-glucose cotransporter 2 (SGLT2) inhibitor, ipragliflozin improved her liver dysfunction clinically and histologically. The serum alanine aminotransferase (ALT) and ferritin levels decreased to normal limits after treatment for four months. Type IV collagen and hyaluronic acid, both of which were serum fibrotic markers, decreased after treatment. Ultrasonography and computed tomography showed a decrease in the fat deposits in her liver. Her liver sample showed marked improvement, especially in steatosis, inflammation, and ballooning. The SGLT2 inhibitor ipragliflozin may be useful as a specific therapeutic drug for NASH.
format Online
Article
Text
id pubmed-5675935
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-56759352017-11-13 The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin Takeda, Akihiko Irahara, Aya Nakano, Atsuko Takata, Emi Koketsu, Yuko Kimata, Kunie Senda, Eri Yamada, Hajime Ichikawa, Kazuhito Fujimori, Takahiro Sumida, Yoshio Intern Med Case Report The patient was a 67-year-old woman with type 2 diabetes and non-alcoholic steatohepatitis (NASH). The administration of the sodium-glucose cotransporter 2 (SGLT2) inhibitor, ipragliflozin improved her liver dysfunction clinically and histologically. The serum alanine aminotransferase (ALT) and ferritin levels decreased to normal limits after treatment for four months. Type IV collagen and hyaluronic acid, both of which were serum fibrotic markers, decreased after treatment. Ultrasonography and computed tomography showed a decrease in the fat deposits in her liver. Her liver sample showed marked improvement, especially in steatosis, inflammation, and ballooning. The SGLT2 inhibitor ipragliflozin may be useful as a specific therapeutic drug for NASH. The Japanese Society of Internal Medicine 2017-09-15 2017-10-15 /pmc/articles/PMC5675935/ /pubmed/28924123 http://dx.doi.org/10.2169/internalmedicine.8754-16 Text en Copyright © 2017 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Takeda, Akihiko
Irahara, Aya
Nakano, Atsuko
Takata, Emi
Koketsu, Yuko
Kimata, Kunie
Senda, Eri
Yamada, Hajime
Ichikawa, Kazuhito
Fujimori, Takahiro
Sumida, Yoshio
The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin
title The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin
title_full The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin
title_fullStr The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin
title_full_unstemmed The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin
title_short The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin
title_sort improvement of the hepatic histological findings in a patient with non-alcoholic steatohepatitis with type 2 diabetes after the administration of the sodium-glucose cotransporter 2 inhibitor ipragliflozin
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675935/
https://www.ncbi.nlm.nih.gov/pubmed/28924123
http://dx.doi.org/10.2169/internalmedicine.8754-16
work_keys_str_mv AT takedaakihiko theimprovementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin
AT iraharaaya theimprovementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin
AT nakanoatsuko theimprovementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin
AT takataemi theimprovementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin
AT koketsuyuko theimprovementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin
AT kimatakunie theimprovementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin
AT sendaeri theimprovementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin
AT yamadahajime theimprovementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin
AT ichikawakazuhito theimprovementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin
AT fujimoritakahiro theimprovementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin
AT sumidayoshio theimprovementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin
AT takedaakihiko improvementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin
AT iraharaaya improvementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin
AT nakanoatsuko improvementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin
AT takataemi improvementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin
AT koketsuyuko improvementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin
AT kimatakunie improvementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin
AT sendaeri improvementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin
AT yamadahajime improvementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin
AT ichikawakazuhito improvementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin
AT fujimoritakahiro improvementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin
AT sumidayoshio improvementofthehepatichistologicalfindingsinapatientwithnonalcoholicsteatohepatitiswithtype2diabetesaftertheadministrationofthesodiumglucosecotransporter2inhibitoripragliflozin

Ejemplares similares